Allan Bradley is the founder of T-Therapeutics. T-Therapeutics has raised $91M in total funding. Latest round: Series A. Based in Cambridge, England.
Professor Allan Bradley founded T-Therapeutics in 2022 to commercialize research on T cell receptor (TCR) therapeutics for cancer and inflammatory disorders. He is based in Cambridge, England, where the company is headquartered at Granta Park. Bradley previously conducted the academic research that led to the company's OpTiMus platform, which harnesses T cells to develop first-in-class cancer medicines.
Full founder directory · Investor directory · Company funding database · Fundraising library